During the past decade, CCAC Lausanne conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "CCAC Lausanne" are "Bone Metastases" (1 trials), "Cancer of the Prostate" (1 trials), "Metastatic Breast Cancer" (1 trials), "Metastatic Prostate Cancer" (1 trials) and "NSCLC Non-small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "CCAC Lausanne" in a lesser frequency.

Most popular intervention types in "CCAC Lausanne" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Denosumab (reduced dosing)" (1 trials), "Denosumab (standard dosing)" (1 trials), "Enzalutamide" (1 trials), "MEDI4736 (anti-PD-L1)" (1 trials) and "Metformin" (1 trials). Other intervention names were less common.

The vast majority of trials in "CCAC Lausanne" are 2 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "CCAC Lausanne". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in CCAC Lausanne, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in CCAC Lausanne, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

CCAC Lausanne has several departments that took part in Clinical trials: "FMH Onkologie/Haematologie" - 2 trials